Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (daclizumab) for Multiple Sclerosis

CAMBRIDGE, Mass. and NORTH CHICAGO, Ill., May 27, 2016 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) approved ZINBRYTA™ (daclizumab), a new once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (RMS), Biogen… http://www.prnewswire.com/news-releases/biogen-and-abbvie-receive-fda-approval-of-once-monthly-zinbryta-daclizumab-for-multiple-sclerosis-300276458.html